Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Authors||Shenshen Lai, Rick Li, Paromita Raha, Yuxiang Hu, Jun Yan, Hong Zhang, Anthony Marotta and Zaihui Zhang|
|Title||Activity of the TAM kinase-targeting compound, SLC-391, is mediated by the engagement of the immune system in CT-26 syngeneic mouse model|
|Abstract Text||Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B148|
|Molecular Profile||Treatment Approach|
|Gene Name||Source||Synonyms||Protein Domains||Gene Description||Gene Role|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|SLC-391||SLC391|SLC 391||AXL Inhibitor 27||SLC-391 is an Axl inhibitor that blocks the phosphotransferase activity of Axl, which potentially stimulates anti-tumor immune response and reverses immunosuppression leading to tumor growth inhibition (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B148).|
|Gene||Variant||Impact||Protein Effect||Variant Description||Associated with drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colon carcinoma||not applicable||SLC-391 + unspecified PD-1 antibody||Preclinical||Actionable||In a preclinical study, treatment with SLC-391 combined with an anti-PD-1 antibody demonstrated synergy and increased overall survival rate in a syngeneic mouse model of colon carcinoma (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B148).||detail...|
|Unknown unknown||colon carcinoma||not applicable||SLC-391||Preclinical||Actionable||In a preclinical study, SLC-391 treatment did not inhibit proliferation of a colon carcinoma cell line in culture, however, inhibited tumor growth by 37% in a syngeneic mouse model (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B148).||detail...|